Patent application number | Description | Published |
20090303006 | SYSTEM AND METHOD FOR WIRELESS COMMUNICATIONS - A method of detecting position of a moving RFID tag relative to an antenna, includes continually receiving a signal from the RFID tag at the antenna. The phase of the received signal over a time period is detected and, based on a maximum detected phase, the position of the RFID tag relative to the antenna is detected. | 12-10-2009 |
20120182129 | SYSTEM AND METHOD FOR WIRELESS COMMUNICATIONS - A method and system for estimating position of a moving RFID tag is provided. The method includes transmitting at least one interrogator signal; receiving, at an interrogator antenna, a reflected signal from the RFID tag; determining phase changes of the reflected signal with respect to the phase of the at least one interrogator signal; weighting the phase changes based on instant power corresponding to the phase changes; producing a phase trajectory for the reflected signal based on the weighted phase changes; and estimating position of the RFID tag relative to the interrogator antenna based on the peak of the phase trajectory for the reflected signal. | 07-19-2012 |
20140095405 | AUTOMATED NOTIFICATION DEVICE - An automated item notification device is described. The automatic notification device is configured to be secured within a drop box and comprises a communication module, a deposit sensor, a camera and processor. The communication module communicates with a remote resource. The deposit sensor senses deposit of an object and provides a wake-up signal in response thereto. The camera captures an image of an interior of the drop box in response to the wake-up signal. The processor is configured to compare the captured image with a previously acquired reference image stored in memory to determine if the object has been received in the drop box. In response to detection that the objected has been received in the drop box, a message is transmitted to the remote resource that the drop box needs to be serviced, and the processor enters an extended sleep mode. In response to detection that the objected has not been received in the drop box, the processor enters a sleep mode. A method for operating the automatic item notification is also described. | 04-03-2014 |
20140306694 | DETERMINING DIRECTION OF AN OBJECT USING LOW FREQUENCY MAGNETIC FIELDS - A method for determining direction of travel of a tag is described. The method includes a tag that receives sample signals from two spatially separate LF magnetic fields generated by an exciter. The received signal strength indicator (RSSI) data associated with each of the sample signals is determined. A first RSSI profile is created for the first LF magnetic fields. A second RSSI profile is created for the second LF magnetic fields. The first and second RSSI profiles are compared to determine a direction of travel of the object. A tag, an exciter and a computer readable medium are configured to facilitate the method. | 10-16-2014 |
Patent application number | Description | Published |
20130345277 | Modulators of GTPase and Use In Relevant Treatment - The present invention relates to molecules which function as selective modulators of the Ras-homologous (Rho) family of small GTPases, in particular, Cdc42 GTPase and their use to treat diseases, for example cancers, including metastatic cancer, genetic and acquired diseases where activation of Cdc42 GTPase plays a pivotal role, such as neurodegenerative diseases, rheumatoid arthritis, atherosclerosis, diabetes type I, autosomal polycystic kidney disease, cystic kidney disease, precystic kidney disease, microbial infections, including | 12-26-2013 |
20150335619 | Modulators of GTPases and Their Use - The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type 1), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of | 11-26-2015 |
Patent application number | Description | Published |
20090208493 | Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors - Compounds disclosed which inhibit ABCB1 transporter protein are useful for treating diseases in which ABCB1 transporter protein mediates the disease state, including numerous cancers, including hematopoietic cancers, including various leukemias, especially T-lineage acute lymphoblastic leukemia, as well as cancerous tumors, especially forms which exhibit multiple drug resistance. Pharmaceutical compositions which comprise an inhibitor of ABCB1 transporter protein and at least one additional anticancer agent, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient are another aspect of the present invention. A flow cytometry based, high-throughput screening (HST) assay that quantifies ABCB1 efflux is also disclosed. Methods of identifying inhibitors of ABCB1, ABCG2 and ABCC1 transporter proteins are also disclosed. | 08-20-2009 |
20110092533 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF - The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases which are mediated through one or more of these receptors include cancer (particularly breast, reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometreitis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disoders such as Parkinson's disease and Alzheimer's disease, as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention. | 04-21-2011 |
20110224141 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER - A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed. | 09-15-2011 |
20120093917 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER - This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical inhibitors of DNA repair proteins (Metnase) and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols. | 04-19-2012 |
20120302582 | NOVEL BIFUNCTIONAL METNASE/INTNASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS OF TREATMENT OF CANCER - This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical bifunctional inhibitors of DNA replication and repair proteins Metnase and/or Intnase (also termed Gypsy Integrase, Gypsy Integrease-1, Gypsy Retransposon Integrase 1, or GIN-I) that simultaneously damage DNA, and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols, including radiation therapy. In preferred embodiments, compounds, compositions and methods of treatment of the invention are used to treat a patient suffering from leukemia (e.g. acute myeloid leukemia (AML) and related cancers. In certain aspects of such treatments, compounds, compositions and methods of treatment of the invention are administered as a monotherapy (in some cases, to patients who have exhibited resistance to Topo IIalpha inhibitors such as VP-16), or are co-administered with a Topo IIalpha inhibitor or other anti-cancer agents as otherwise described herein or in combination with radiation therapy. | 11-29-2012 |
20140343347 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER - A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed. | 11-20-2014 |
20150087886 | NOVEL BIFUNCTIONAL METNASE/INTNASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS OF TREATMENT OF CANCER - This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical bifunctional inhibitors of DNA replication and repair proteins Metnase and/or Intnase (also termed Gypsy Integrase, Gypsy Integrease-1, Gypsy Retransposon Integrase 1, or GIN-1) that simultaneously damage DNA, and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols, including radiation therapy. | 03-26-2015 |